LOS ANGELES, CA - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience across global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener's appointment comes at a critical time for VERAXA as it advances its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats. His extensive background in capital markets and corporate finance is likely to be instrumental in navigating the complex financial landscape of biotech development, where securing funding and managing resources are paramount. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
This move signals VERAXA's commitment to strengthening its financial leadership as it prepares for potential clinical milestones and possible partnerships. The company's BiTAC(R) platform, which is based on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), represents a novel approach to cancer therapy. By bringing in a CFO with deep experience in global finance, VERAXA aims to better position itself for the capital-intensive process of drug development and commercialization.
For industry observers, this appointment underscores the importance of financial expertise in the biotech sector, especially for companies with promising but costly research pipelines. Willener's track record in managing large investment portfolios and leading M&A could be a sign that VERAXA is exploring strategic options, including partnerships, licensing deals, or even an eventual acquisition. The company's focus on next-generation antibody-based therapeutics places it in a competitive field, and having a CFO who understands both science and finance is crucial for long-term success.
VERAXA Biotech is building what it describes as a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline into clinical development and beyond. Willener's appointment is expected to support the company's capital strategy and strategic opportunities as it continues to develop its proprietary BiTAC(R) technology platform.
The company's stock is traded on the NASDAQ under the symbol VRXA, and this leadership change may be viewed by investors as a positive step toward strengthening its financial foundation. The full press release is available at this link. For the latest updates and news relating to VRXA, the company’s newsroom can be accessed at IBN's VRXA newsroom. As with any forward-looking statements, the company advises caution, noting risks and uncertainties that could affect actual results. More details on these factors can be found in the company's SEC filings and in the full terms and disclaimers on the InvestorBrandNetwork website at IBN's disclaimer page.
